Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
jimsgtx,I vote yes 4 good news tomorrow. Information on the sensibility of anti-PS is permeating the right spaces, and like a good wine forcing the cork after awhile, PPHM is about to burst onto the world stage. PPHM Bavituximab is not a killer, but a facilitator of body cells that are killers. Best? I can assure everyone herein reading that Bavi is the harbinger of an amazing technology boom in monoclonal antibodies. It's all we have until we get better genetic manipulation and cloning. PPHM is positioned to become an incredible giant the bioequivalent Apple and Microsoft pooled together. Let's see what we common stock holders get for get for our altruistic investing. This whole scenario gets interestinger and interestinger. Good luck all. Wish I were at the meeting, but someone has to take care of patients.
thanks goodpickin', sounds like someone here busted the agency's cover, and they had to go public. about time. but there is nothing more unethical than raising false hopes, and I think PPHM has gone out of its way to stay on the right side of that line. as I said a couple weeks ago, it is beyond credibility to believe that anti-PS has not been tried, at least in combo, against Ebola.
Somebody please bring me up to date on what happened/what was said this morning before the market opened. It is difficult to tell after sifting thru 3 pages of posts. Thanks. A working doc.
shipbuilder. nicely written. agreed that the spin-offs from Bavituximab anti-cancer campaign will probably end up being more valuable the the primary target. we'll see. we stockholders DO work hard for our money, and one of our obligations is to be certain nobody steals it from us...
theOtherGuy, I am among the crowd here who thinks the PPHM corporate officers DID deliver on PPS stimulus, and were sabotaged by the September debacle, an event which would have knocked the underpinnings from the strongest among us. I am looking at a [corporate] survival miracle at this point, and can point to several moves SK and other officers made at that time and prior to that time (read, Garnick)to pull possible/probable success out of disaster. They cannot do more than they can ethically and legally do at this point. I think you know I am as frustrated as you are about all of this. However, anti-phospholipid antibody platform is here to stay. The question is who gets it, and for what price. We've paid for all the safety data. No time to destroy the creation.
InternetForumUser, no. I did not listen to SK's attempt to rationalize PPHM stock price/market cap, but I hope there are other corporate officers who could address that question better. I think SK does a good job of communicating to the more science-minded listener
theOtherGuy: I don't get it. What evidence is out there that they (management) care less than you or I about the market cap?
"I just cannot believe management's lack of care for the market cap - especially going into the ASM"
Carboat, after re-reading last month conference call I am impressed by all that was disclosed rather than how much is being hidden. It is a fine line between unethical hype and ethical disclosure. My enthusiasm was actually restored after reading the text. Give it a shot, and if you still have doubts about a specific PPHM development program we can toss it back and forth here. PII enrollment has gone well; Liver results soon; more on breast cancer in the next few days/weeks, etc.
right on, goodjohnhunting...or the wheels.
cj, I just read the 9/9/14 PPHM conference call transcription. Thanks again. Most impressive IMO. Some of my take away:
King:
--a future goal is to touch on the dendritic cell vaccines as well as antigen-based vaccines;
--We have already started to see the fruits of these collaborations with very encouraging results in preclinical models of Melanoma, Colon Cancer, and most recently Breast Cancer when combining bavituximab with other immune checkpoint inhibitors
--regarding breast cancer: "the investigator has prepared a manuscript, which we expect to be submitted for publication shortly. It’s going to contain obviously the results previously, but in a fuller description..."So there will be new date obviously then?” Joe Shan: Yes.
--So, when we think about partnering we’re really looking at expanding into some of these new indications, and clearly Breast Cancer & Liver Cancer are right now are at the top of the list, based
--clinical data will eventually trump all that [e.g. absence of stock price gains, lack of public recognition], and that’s the reason executing on the Phase III SUNRISE trial is so important as a backbone to getting the recognition for this [Bavi] program
Liver:
--We are continued to be encouraged by the updates from the principal investor, Dr. Adam Yopp of the Univ. of Texas SW Medical Center in Dallas, and we look forward to his presentation of the full clinical results at a future conference. Meanwhile, as part this trial, we have been able to generate translational data showing immune changes in patient tumor samples which are consistent with the immuno-modulating mechanism observed in preclinical models.
--revisiting prior observations:
"We can go back quite a ways to published data where actually [Bavi works qyute well with] radiotherapy as an adjuvant and a vaccine if you will.
IMO a significant possibility exists that PPHM Bavituximab has already been tried in humans with Ebola. Not trying it by this time seems incredible. Looking back,
"TUSTIN, CA, and ORLANDO, FL -- (MARKET WIRE) -- 11/17/10 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced preclinical data demonstrating its lead antibody bavituximab's ability to bind to virus particles and virus-infected cells of five viruses that cause viral hemorrhagic fever (VHF), including the highly lethal Ebola virus. Additionally, Peregrine reported bavituximab in combination with the antiviral drug ribavirin improved survival by up to 50% compared to either drug used as a monotherapy in several models of VHF. These data are being presented at the 2010 Chemical and Biological Defense Science and Technology Conference in Orlando, Florida."
It is far more likely in my mind that Bavi does not work in late stage Ebola than that Bavi has not been tried. I also think there is a significant chance that M_APP pharmaceuticals, manufacturer of "Z_M-APP" is a front for an agency that need not be named, and is primarily involved in M(onoclonal antibody) applications which might have APPlication in various fields of governmental interest.
cj, thanks for the reminder. this study is a bit more technically difficult to understand, but does confirm that PGN632 and two of its clones inhibit HIV 1 as determined by a very reliable assay, the PBMC (peripheral blood monocyte/macrophage count) assay. I remain unconvinced that PII lung cancer trials are the only arrows in the PPHM quiver.
Paul, I think it was 2012. Chey? I'm working and cannot look it up
chey, actually, unbelievable. Your reference quoted: "Our data show that the PS-targeting mAb PGN632 is at least equally efficacious compared with Zirgan® in reducing corneal SLE (slit lamp evaluation) scores and minimizing the ocular clinical symptoms. By providing symptomatic relief in addition to reducing corneal SLE scores, PGN632 could become a drug of choice for treatment of ocular herpes. This herpes corneal treatment for PGN632 is big too. Was this info. posted here previously? I am jazzed! (for a change).
traff0, I suppose Bavi-viral is similar to Bavi-cancer, in that it will prove most effective when used very early on when the immune system is not swamped by disease...and that could explain why PPHM might not want to get involved. We already have problems enough trying to establish/prove efficacy in trials on mostly hopeless cases of cancer. Probably the biggest single tragedy in this entire scenario is that we cannot dare use it earlier. All in time...hopefuly.
Chey, would love to be a fly on the wall re. Bavi vs. Ebola...or Bavi vs. any viral indication at this point. Seems the anti-viral crowd would be looking at Bavi very intensely, at least as part of the mix, given its safety profile. Of course there is always a chance it has already been tried as part of an anti-viral cocktail, and not publicized.
there is no more elegant display of PPHM reality than today's "trading" which bears no relationship to active trading, but rather some market maker's bored and frustrated effort to create an impression of "activity". this situation is not a negative or positive, but simply evidence that stockholders are holding and waiting for news. all is noise until news.
another good one. thanks dia76ca
good post geo, straight thinkin'.
lemmy,thanks. As long as there is minimal stock trading hands, as with PPHM, in a situation with a huge float, as with PPHM, I have few concerns about the future. What I am seeing is disinterest. Whether or not the disinterest is justifiable remains to be seen. I've been here long enough to see most the ill-informed gamblers get discouraged and leave the table. Many (but not all) of the more informed investors who understand the science are still (impatiently) aboard. PPHM science has held up for a decade of very rapid technological change. I think it will probably hold up and even expand in the coming decade. We'll see.
eyebuy, when you say, "there's zero chance", things often start popping. PPHM stock behavior has been so bad I have had to start taking anti-nauseants. I am trying to build up a cash reserve to increase holdings if and when, and meanwhile watch my portfolio value dwindle. Still holding and hoping....
Wonder if liver data is being priced into PPHM stock
cheynew, I think UTSW and stockholders have the clout to make changes, but the catalyst simply is not there at this point. It would be utter stupidity to make changes now. I agree with EastCoastGuy: laser focus at this time and no distractions.
none of these partnering conference scenarios seem real to me, and have not for many years. I agree with the pimp in the background scenario elaborated so nicely by BioBS, but attendance at these conferences is nothing but a quid pro quo for a touch of publicity and a an effort to help fill the playbill for the conference sponsors. ridiculous really. either PPHM has the goods and is in stratospheric big pharma company, or we are all wasting our time. What BP out there is not aware of Bavituximab at this point? absolutely ridiculous. a well-written narrative of Bavi's "movement" through the pipeline would be a story well-worth reading. farce of the highest order, really. wish I had the energy to tell it.
lorekarf, you may possibly (but not definitely) be correct about one or more "big players" holding PPHM stock price down, and even though the concept may be labeled "paranoid", irrational, or ill-informed, there is still good reason to consider it a possibility, if not a likelihood. I have said for years that a big pharma could not find a cheaper way to research a new platform; and nobody who has followed this stock for a decade could say that share price events here have been strictly, or even remotely, "marketplace driven". Even recent day-to-day behavior of the stock does not seem "real" to me. But I (obviously) have no expertise in the stock market. Similar to a large percentage of the longs here, I have been attracted to PPHM because the science is sensible and the upside risk seems attractive, but a large number of those still here, either lurking or posting, purchased on good news have seen investment dollars trapped when the stock price slumps and goes into a holding pattern similar to what we've seen for weeks.. It is that repetitive failure to grow value that keeps most gamblers away. There is no reflection of Avid growth in monoclonal antibody production, and little value attributed to the progress in knowledge of the anti-PS platform. Stalled at $.35/share pre-reverse split is an enormous disconnect IMO. Still holding and hoping. Cheers!
hopefilled, nice. My wife is a bit more prone to deleted expletives when she episodically inquires into the value
of our PPHM. I respond with my usual homily (used often here) of how we can use shares as Christmas stocking stuffers for our children and (future) grandkids. Amazing, the public (and scientific community) indifference to our PPHM. When will they see the light!?
jbainseky,, thanx, good stuff. what we've grown to expect eom
goodhuntingjohn:wow!iportantstuff.thanx.eom
cloaked, agreed. One of you finest posts. thanks. eom
Need to recharge you PPHM enthusiasm batteries? I took time this AM to listen to all of Dr.Brekken's 5-28-14 “Cancer Immunotherapy”webinar. It is cjgaddy post 178905 (thanks CJ). It might be a bit mind-numbing to those no immunology vocabulary, but imo the data presented makes it abundantly clear that anti-PS therapy is going to happen, and especially in combination with irradiation therapy. The data set for melanoma combination-immunotherapy was much less compelling than that for Bavi+irradiation in lung cancer and Bavi+castration (+irradiation?) for prostate cancer. All we can do at this point is await results.
wook, Bavi approval already built into pps?
dumbster, this has been going on for more than a decade, not weeks or months. simple: downward forces > upward forces.
everyone has their ideas about who the former are. WE are the latter.
tech0200, good question, Either a partner was fantasy then or the price to play has gone up. It could also be "neither/but". We are in a holding pattern pending results, pure and simple. Thank gawd for Garnick and his minions. Without him we probably would have run out of fuel and "stuck it". Not a word out of China about Cotara, or from Europe on 2C3....or, or....
Disappointed as everyone here re. stock price. Mostly a lurker now, I continue to enjoy your posts. I am not posting much because I am working full-bore, and because y'all cover the bases well re. market mechanics and science.
Over and over I ask myself whether the stock price could truly be a reflection of its value; or if short selling is the root cause; or if active defensive intervention is at play by potential competitors to discourage investment and financially cripple progress. Every price spike is fiercely batted down, and new investors are trapped with progressively lower value. The start of PIII would be the logical point for speculators to pile in, and yet nothing. The absence of information out of Tustin is no surprise, and is sensible, but the absence of any trace of upward momentum in this bull market is depressing. Wish I had the courage to increase my holding...or a good reason to do so. For now I continue to hold in the low 6 digit realm. Remain the most puzzled by absence of any information or major $$ inflow from Russia, Denmark, or China. Cheers! And thanks to all of you for the humor, sleuthing, and interesting posts.
dia76ca: one of the funnier posts ever..a million tanks to you...
jeez BCS Paladin, agree 100%. unusual. eom
wook, I share your concern. When I read the (interesting) info you alluded to I was somewhat overwhelmed. It brings into sharp focus the "goliath v. david" quality of competition PPHM has been facing. We need some positive results from PIII...and soon.
RobertC: great post. This is, in fact, an interesting avenue of study, and appears to be a Bavi competitor, or more likely, a Bavi companion treatment. Interestingly, rather than targeting on phosphatidylserine (PS) it targets on synthesis of "PI", phosphatidylinositol, a sibling/cousin of PS. The "delta inhibitors" are a "head turner" for cancer treatment potential, especially lymphoma/leukemia/Hodgkins where there have been some startling results reported, but there are no claims for cure of solid tumors. Similar to Bavi the delta inhibitors seem to increase survival time with fewer metastases, longer time to recurrence,and evidence of increased immune recognition of tumor. You were concerned about oral form of Bavituximab. Apparently it is tremendously active when delivered in a nasal spray. Don't think the delta inhibitors have that yet!
Calistoga Pharmaceuticals, the leader in US delta inhibitors, sold out to Gilead 2-3 years ago:
http://www.xconomy.com/seattle/2011/02/23/calistoga-hands-the-keys-to-gilead-bets-it-can-make-cancer-a-chronic-disease-like-hiv/
http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/1777 Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
revenuemonster: don't agree Cotara a niche product. Agree that glioblastomamultiforme is a niche cancer. If Cotara does dent in GBM it can easily be used off label, once approved for GBM, for any tumor >2 cm with necrotic central core. And there are plenty of oncologists who understand the chemistry and MOA of I131 (and plenty of non-operable solid cancers that size and bigger).
Hypi, immunotherapy has had its ups and downs in the cancer therapeutic arena, and is currently the darling of the oncology avant garde, but meanwhile back in the clinic the same old principles of tried and treated treatments are still mostly employed. If a cancer is visible and accessible surgical extirpation will remain the treatment of choice in the foreseeable future. Nobody is going to treat a large cancer with immunotherapy alone. These agents, such as PPHM Bavituximab will be used to "prime" the target; immunologically "read" the target; stimulate the immune system to recognize the target; and then facilitate the body's manufacture of its own cancer killer antibodies to nullify growth or kill metastases and prevent recurrence. Likewise, external beam irradiation therapy will continue to be used into the foreseeable future because it is a killer of cancers (and normal cells), but it also promotes mutations. Cotara, a MAB carrying radioactive iodine, homes-in/docks on DNA-Histone, a component of dead/necrotic cells found in enormous concentrations in the center of cancers where rapidly multiplying cancer cells invariably outgrow their own blood supply and die. This miasma in the center of tumors hides some viable tumor cells which, when the "heat" is off, reconstitute and cause recurrences. Cotara kills from the inside out. Most cytotxics won't penetrate this area of tumor, including surface irradiation and chemo. In a perfect world an agent like ICT-107, about which you just posted, AND Cotara could be used in tandem and in synergy to provide even more survival time for sufferers of glioblastoma multiforme. Once approved for GBM Cotara can be used for other similar indications. No question but what anti-DNA histone is sensible. The question is will it be commercialized by PPHM, and in its present clunky form, or another.